# Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease

**Authors:** Sulin Cheng, Petri Wiklund, Reija Autio, Ronald Borra, Xiaowei Ojanen, Leiting Xu, Timo Törmäkangas, Markku Alen

PMC · DOI: 10.1371/journal.pone.0138889 · PLoS ONE · 2015-10-06

## TL;DR

Early signs of fatty liver disease are linked to changes in amino acid metabolism and fat tissue function, independent of obesity or insulin resistance.

## Contribution

This study identifies early metabolic and adipose tissue changes associated with non-alcoholic fatty liver disease in middle-aged individuals.

## Key findings

- Increased branched-chain and aromatic amino acids are linked to early liver fat accumulation.
- Adipose tissue shows reduced BCAA catabolism and energy metabolism in NAFLD.
- Reduced BCAA catabolism correlates with higher serum BCAA and liver fat content.

## Abstract

Fatty liver is a major cause of obesity-related morbidity and mortality. The aim of this study was to identify early metabolic alterations associated with liver fat accumulation in 50- to 55-year-old men (n = 49) and women (n = 52) with and without NAFLD.

Hepatic fat content was measured using proton magnetic resonance spectroscopy (1H MRS). Serum samples were analyzed using a nuclear magnetic resonance (NMR) metabolomics platform. Global gene expression profiles of adipose tissues and skeletal muscle were analyzed using Affymetrix microarrays and quantitative PCR. Muscle protein expression was analyzed by Western blot.

Increased branched-chain amino acid (BCAA), aromatic amino acid (AAA) and orosomucoid were associated with liver fat accumulation already in its early stage, independent of sex, obesity or insulin resistance (p<0.05 for all). Significant down-regulation of BCAA catabolism and fatty acid and energy metabolism was observed in the adipose tissue of the NAFLD group (p<0.001for all), whereas no aberrant gene expression in the skeletal muscle was found. Reduced BCAA catabolic activity was inversely associated with serum BCAA and liver fat content (p<0.05 for all).

Liver fat accumulation, already in its early stage, is associated with increased serum branched-chain and aromatic amino acids. The observed associations of decreased BCAA catabolism activity, mitochondrial energy metabolism and serum BCAA concentration with liver fat content suggest that adipose tissue dysfunction may have a key role in the systemic nature of NAFLD pathogenesis.

## Linked entities

- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209), NAFLD (MONDO:0013209)

## Full-text entities

- **Genes:** GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ECI2 (enoyl-CoA delta isomerase 2) [NCBI Gene 10455] {aka ACBD2, DRS-1, DRS1, HCA88, PECI, dJ1013A10.3}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, IDH3B (isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta) [NCBI Gene 3420] {aka RP46}, CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116] {aka ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P}, HIBADH (3-hydroxyisobutyrate dehydrogenase) [NCBI Gene 11112] {aka NS5ATP1}, NDUFA12 (NADH:ubiquinone oxidoreductase subunit A12) [NCBI Gene 55967] {aka B17.2, DAP13, MC1DN23}, ADH5 (alcohol dehydrogenase 5 (class III), chi polypeptide) [NCBI Gene 128] {aka ADH-3, ADHX, AMEDS, BMFS7, FALDH, FDH}, OXCT1 (3-oxoacid CoA-transferase 1) [NCBI Gene 5019] {aka OXCT, SCOT}, ADH1B (alcohol dehydrogenase 1B (class I), beta polypeptide) [NCBI Gene 125] {aka ADH2, HEL-S-117}, NDUFA10 (NADH:ubiquinone oxidoreductase subunit A10) [NCBI Gene 4705] {aka CI-42KD, CI-42k, MC1DN22}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, COX5B (cytochrome c oxidase subunit 5B) [NCBI Gene 1329] {aka COXVB}, HADH (hydroxyacyl-CoA dehydrogenase) [NCBI Gene 3033] {aka HAD, HADH1, HADHSC, HCDH, HHF4, MSCHAD}, MCEE (methylmalonyl-CoA epimerase) [NCBI Gene 84693] {aka GLOD2, MCE, MMCE}, Got2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 25721] {aka ASPATA, mAAT}, HIBCH (3-hydroxyisobutyryl-CoA hydrolase) [NCBI Gene 26275] {aka HIBYLCOAH}, PCCB (propionyl-CoA carboxylase subunit beta) [NCBI Gene 5096], ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, IDH3A (isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha) [NCBI Gene 3419] {aka RP90}, ALDH9A1 (aldehyde dehydrogenase 9 family member A1) [NCBI Gene 223] {aka ALDH4, ALDH7, ALDH9, E3, TMABA-DH, TMABADH}, ECI1 (enoyl-CoA delta isomerase 1) [NCBI Gene 1632] {aka DCI}, ATP5F1A (ATP synthase F1 subunit alpha) [NCBI Gene 498] {aka ATP5A, ATP5A1, ATP5AL2, ATPM, COXPD22, HEL-S-123m}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ACADVL (acyl-CoA dehydrogenase very long chain) [NCBI Gene 37] {aka ACAD6, LCACD, VLCAD}, HADHA (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) [NCBI Gene 3030] {aka ECHA, GBP, LCEH, LCHAD, MLCL AT, MTPA}, CYC1 (cytochrome c1) [NCBI Gene 1537] {aka MC3DN6, UQCR4}, ATP6AP1 (ATPase H+ transporting accessory protein 1) [NCBI Gene 537] {aka 16A, ATP6IP1, ATP6S1, Ac45, CF2, VATPS1}, ACSL1 (acyl-CoA synthetase long chain family member 1) [NCBI Gene 2180] {aka ACS1, FACL1, FACL2, LACS, LACS1, LACS2}, PDHB (pyruvate dehydrogenase E1 subunit beta) [NCBI Gene 5162] {aka E1beta, PDHBD, PDHE1-B, PDHE1B, PHE1B}, HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta) [NCBI Gene 3032] {aka ECHB, MSTP029, MTPB, MTPD, MTPD2, TP-BETA}, MCCC1 (methylcrotonyl-CoA carboxylase subunit 1) [NCBI Gene 56922] {aka MCC-B, MCCA, MCCCalpha}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, SUCLG1 (succinate-CoA ligase GDP/ADP-forming subunit alpha) [NCBI Gene 8802] {aka GALPHA, MTDPS9, SUCLA1}, MMUT (methylmalonyl-CoA mutase) [NCBI Gene 4594] {aka MCM, MUT}, DLD (dihydrolipoamide dehydrogenase) [NCBI Gene 1738] {aka DLDD, DLDH, E3, GCSL, LAD, OGDC-E3}, ALDH7A1 (aldehyde dehydrogenase 7 family member A1) [NCBI Gene 501] {aka ATQ1, EPD, EPEO4, PDE}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, Ggt1 (gamma-glutamyltransferase 1) [NCBI Gene 116568] {aka GGLUT, Ggt, Ggtp}, PCCA (propionyl-CoA carboxylase subunit alpha) [NCBI Gene 5095], AUH (AU RNA binding methylglutaconyl-CoA hydratase) [NCBI Gene 549], COX5A (cytochrome c oxidase subunit 5A) [NCBI Gene 9377] {aka COX, COX-VA, MC4DN20, VA}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, DLST (dihydrolipoamide S-succinyltransferase) [NCBI Gene 1743] {aka DLTS, KGD2, PGL7, PPGL7}, ATP5MC3 (ATP synthase membrane subunit c locus 3) [NCBI Gene 518] {aka ATP5G3, DYTSPG, P3}, SUCLG2 (succinate-CoA ligase GDP-forming subunit beta) [NCBI Gene 8801] {aka G-SCS, GBETA, GTPSCS}, TTF2 (transcription termination factor 2) [NCBI Gene 8458] {aka HuF2, ZGRF6}, PCK1 (phosphoenolpyruvate carboxykinase 1) [NCBI Gene 5105] {aka PCKDC, PEPCK-C, PEPCK1, PEPCKC}, CS (citrate synthase) [NCBI Gene 1431], SUCLA2 (succinate-CoA ligase ADP-forming subunit beta) [NCBI Gene 8803] {aka A-BETA, A-SCS, LINC00444, MTDPS5, SCS-betaA}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BCKDHB (branched chain keto acid dehydrogenase E1 subunit beta) [NCBI Gene 594] {aka BCKDE1B, BCKDH E1-beta, E1B, MSUD1B, OVD1B}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, TBC1D4 (TBC1 domain family member 4) [NCBI Gene 9882] {aka AS160, NIDDM5}, VAV1 (vav guanine nucleotide exchange factor 1) [NCBI Gene 7409] {aka VAV}, ATP5MG (ATP synthase membrane subunit g) [NCBI Gene 10632] {aka ATP5JG, ATP5L}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}
- **Diseases:** NAFLD (MESH:D065626), hepatitis (MESH:D056486), cirrhosis (MESH:D005355), hepatic mitochondrial dysfunction (MESH:D028361), type I/II diabetes (MESH:D003922), cancer (MESH:D009369), liver, pancreas or heart disease (MESH:D008107), metabolic (MESH:D008659), dyslipidemia (MESH:D050171), LFC (MESH:D017093), Adipose Tissue Dysfunction (MESH:D018205), type 2 diabetes (MESH:D003924), insulin resistance (MESH:D007333), NASH (MESH:D005235), FM (MESH:C536030), Inflammation (MESH:D007249), hypertension (MESH:D006973), cardiac diseases (MESH:D006331), hyperglycemia (MESH:D006943), fatty liver (MESH:D005234), hyperinsulinemia (MESH:D006946), ectopic fat (MESH:D004620), EMCL (MESH:D011017), AAA (MESH:C537437), obese (MESH:D009765)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** I148M

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4595021/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4595021/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC4595021/full.md

---
Source: https://tomesphere.com/paper/PMC4595021